Literature DB >> 27531952

A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver.

Feng Li1, Pengcheng Wang1, Ke Liu1, Mariana G Tarrago1, Jie Lu1, Eduardo N Chini1, Xiaochao Ma2.   

Abstract

Overdose of isoniazid (INH), an antituberculosis drug, can be life-threatening because of neurotoxicity. In clinical practice for management of INH overdose and acute toxicity, the potential of INH-induced hepatotoxicity is also considered. However, the biochemical basis of acute INH toxicity in the liver remains elusive. In the current study, we used an untargeted metabolomic approach to explore the acute effects of INH on endobiotic homeostasis in mouse liver. We found that overdose of INH resulted in accumulation of oleoyl-l-carnitine and linoleoyl-l-carnitine in the liver, indicating mitochondrial dysfunction. We also revealed the interactions between INH and fatty acyl-CoAs by identifying INH-fatty acid amides. In addition, we found that overdose of INH led to the accumulation of heme and oxidized NAD in the liver. We also identified an INH and NAD adduct in the liver. In this adduct, the nicotinamide moiety in NAD was replaced by INH. Furthermore, we illustrated that overdose of INH depleted vitamin B6 in the liver and blocked vitamin B6-dependent cystathionine degradation. These data suggest that INH interacts with multiple biochemical pathways in the liver during acute poisoning caused by INH overdose.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27531952      PMCID: PMC5074471          DOI: 10.1124/dmd.116.070920

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  53 in total

1.  Suicidal ingestion of isoniazid: an uncommon cause of metabolic acidosis and seizures.

Authors:  E S Bear; P F Hoffman; S R Siegel; R E Randal
Journal:  South Med J       Date:  1976-01       Impact factor: 0.954

2.  Suicidal Isoniazid poisoning.

Authors:  Haji Khan Khoharo; Shuaib Ansari; Allauddin Abro; Fatima Qureshi
Journal:  J Ayub Med Coll Abbottabad       Date:  2009 Apr-Jun

3.  A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis.

Authors:  Rachel J Church; Hong Wu; Merrie Mosedale; Susan J Sumner; Wimal Pathmasiri; Catherine L Kurtz; Mathew T Pletcher; John S Eaddy; Karamjeet Pandher; Monica Singer; Ameesha Batheja; Paul B Watkins; Karissa Adkins; Alison H Harrill
Journal:  Toxicol Sci       Date:  2014-05-20       Impact factor: 4.849

4.  The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.

Authors:  Bing Chen; Jin-Heng Li; Yi-Min Xu; Jie Wang; Xiao-Mei Cao
Journal:  Clin Chim Acta       Date:  2005-09-21       Impact factor: 3.786

Review 5.  Present epidemiology of tuberculosis. Prevention and control programs.

Authors:  Àngels Orcau; Joan A Caylà; José A Martínez
Journal:  Enferm Infecc Microbiol Clin       Date:  2011-03       Impact factor: 1.731

6.  Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine.

Authors:  Feng Li; Yan Miao; Lirong Zhang; Sarah Ann Neuenswander; Justin T Douglas; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2011-08-16       Impact factor: 3.614

Review 7.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 8.  Metabolism of sulfur-containing amino acids.

Authors:  M H Stipanuk
Journal:  Annu Rev Nutr       Date:  1986       Impact factor: 11.848

Review 9.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

10.  Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome.

Authors:  Carlos Escande; Veronica Nin; Nathan L Price; Verena Capellini; Ana P Gomes; Maria Thereza Barbosa; Luke O'Neil; Thomas A White; David A Sinclair; Eduardo N Chini
Journal:  Diabetes       Date:  2012-11-19       Impact factor: 9.461

View more
  5 in total

1.  Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver.

Authors:  Junjie Zhu; Jie Lu; Hung-Chun Tung; Ke Liu; Jianhua Li; Denis M Grant; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

2.  Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Authors:  Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2017-09-06       Impact factor: 5.858

3.  CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor.

Authors:  Junjie Zhu; Pengcheng Wang; Feng Li; Jie Lu; Amina I Shehu; Wen Xie; Deborah McMahon; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2018-10-17       Impact factor: 5.858

4.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

Review 5.  The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases.

Authors:  Kelly A Hogan; Claudia C S Chini; Eduardo N Chini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.